10‐Year Observational Follow‐Up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution due to limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Erland Erdmann, Sarah Harding, Hung Lam, Alfonso Perez Tags: ORIGINAL ARTICLE Source Type: research
More News: Actos | Bladder Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Attack | Obesity | Prostate Cancer | Statistics | Stroke | Study